INT315851

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 0.85
Pain Relevance 0.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transmembrane transporter activity (SLC22A1) plasma membrane (SLC22A1) transmembrane transport (SLC22A1)
Anatomy Link Frequency
stem cells 1
SLC22A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Potency 8 87.76 High High
rheumatoid arthritis 2 28.32 Quite Low
cytokine 2 13.44 Low Low
Central nervous system 14 5.00 Very Low Very Low Very Low
corticosteroid 4 5.00 Very Low Very Low Very Low
headache 4 5.00 Very Low Very Low Very Low
imagery 2 5.00 Very Low Very Low Very Low
cva 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myeloid Leukemia 170 97.88 Very High Very High Very High
Cancer 12 96.86 Very High Very High Very High
Fever 6 81.16 Quite High
Colitis 2 80.36 Quite High
Cytomegalovirus Infection 2 79.48 Quite High
Pneumonia 2 79.28 Quite High
Pleural Effusion 36 78.76 Quite High
Lymphocytosis 4 74.60 Quite High
Systemic Lupus Erythematosus 2 51.64 Quite High
Leukemia 30 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These include upregulation of the ABCB1 or ABCG2 drug efflux pumps,58,63,64 downregulation of human organic cation transporter 1 (hOCT1) drug influx transporters,65,66 overexpression of Lyn, a Src-family kinase,67 and other Bcr-Abl-independent mechanisms.
Negative_regulation (downregulation) of hOCT1
1) Confidence 0.01 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886328 Disease Relevance 0.59 Pain Relevance 0.04
Imatinib has been reported to be a substrate and/or an inhibitor for the ABCG2 drug efflux pump which is overexpressed in many human tumors and also found to be functionally expressed in CML stem cells.64,83,84 The drug transporter hOCT1 mediates the active transport of imatinib into cells, and inhibition of hOCT1 decreases the intracellular concentration of imatinib, which may predict for a less favorable molecular response.65,66
Negative_regulation (inhibition) of hOCT1 in stem cells associated with myeloid leukemia and cancer
2) Confidence 0.01 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886328 Disease Relevance 0.26 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox